Shopping Cart
Remove All
Your shopping cart is currently empty
Nurulimab
(Synonyms: BCD-145, BCD145) Copy Product Info
🥰Excellent
Synonyms: BCD-145, BCD145
Catalog No. T77103 Copy Product Info
🥰Excellent
Nurulimab (BCD-145) is an immune checkpoint inhibitor composed of a humanized monoclonal antibody and is also a CTLA-4 antagonist. By binding to CTLA-4, Nurulimab lifts the inhibitory brake on T-cell activation, enhances the function of effector T cells, and reduces the immunosuppressive activity of Tregs. In preclinical studies, the combination of nurulimab with the PD-1 inhibitor prolgolimab (BCD-100) produced synergistic antitumor effects. Nurulimab has demonstrated good tolerability and is suitable for use in studies of solid tumors such as melanoma, non-small cell lung cancer, and renal cell carcinoma. Nurulimab may also be used in studies of skin and musculoskeletal disorders.
Cas No. 2168561-20-2
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $158 | - | In Stock | |
| 5 mg | $413 | - | In Stock | |
| 10 mg | $662 | - | In Stock | |
| 25 mg | $983 | - | In Stock | |
| 50 mg | Preferential | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:95.5% (SDS-PAGE); 97.3% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Nurulimab (BCD-145) is an immune checkpoint inhibitor composed of a humanized monoclonal antibody and is also a CTLA-4 antagonist. By binding to CTLA-4, Nurulimab lifts the inhibitory brake on T-cell activation, enhances the function of effector T cells, and reduces the immunosuppressive activity of Tregs. In preclinical studies, the combination of nurulimab with the PD-1 inhibitor prolgolimab (BCD-100) produced synergistic antitumor effects. Nurulimab has demonstrated good tolerability and is suitable for use in studies of solid tumors such as melanoma, non-small cell lung cancer, and renal cell carcinoma. Nurulimab may also be used in studies of skin and musculoskeletal disorders. |
| Synonyms | BCD-145, BCD145 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | CTLA-4/CD152 |
| Molecular Weight | 145.01 kDa |
| Cas No. | 2168561-20-2 |
| Isotype | Human IgG1 kappa |
| Recommended Isotype Control |
| Storage | Store at low temperature -20°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Keywords
Preview
Related Tags: Nurulimab chemical structure | Nurulimab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.